High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma
High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma
A prospective pilot trial was proposed to patients with DLBCL, with IH or high adjusted IPI,
 up to the age of 60 y.o. This program consisted of 2 courses of high-dose R-CHOP-like
 regimen, followed by a course of high-dose methotrexate with cytarabin. For patients who
 achieved at least a PR, ASCT started with a BEAM regimen.
Superiority of HDT with autologous stem cell transplantation (ASCT) in the upfront treatment
 of poor-risk DLBCL remains an option for intermediate-high (IH) or high IPI young adults. We
 updated results of the prospective trial Goelams 074 to evaluate long-term efficacy and
 toxicity in 42 patients who underwent HDT with ASCT.
Inclusion Criteria:

 -  Age 18 to 60 y.o

 -  Aggressive Large B-Cell Lymphoma (CD20+)

 -  Ann Arbor stage III, IV

 -  IH or high adjusted IPI

 -  signed inform consent

 Exclusion Criteria:

 -  Age < 18 ou > 60 y.o

 -  other type of lymphoma

 -  serology VIH +

 -  other neoplasms apart from basal cell carcinoma or situ carcinoma